FDA grants breakthrough designation to trastuzumab deruxtecan (Enhertu) for metastatic non-small cell lung cancer

The award relates to investigation of this HER2-directed antibody-drug conjugate in patients whose tumours have an HER2 mutation and with disease progression on or after platinum-based therapy.

Source:

PharmaTimes